Nevertheless, with the recent results from the ADAURA study demonstrating markedly prolonged disease-free survival with adjuvant osimertinib in resected EGFR mutant NSCLC, the enthusiasm for following suit with ALK has mounted, as ADAURA OS data are maturing (133). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.